MedDataX Logo

Influence of Periodontitis and Coronary Heart Disease on Galectin-3

NCT ID: NCT04564950

Last Updated: 2020-12-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

155 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-04-01

Study Completion Date

2018-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study was to analyze the association between serum and salivary Galectin-3 levels in patients with periodontitis. Furthermore, the objective was to determine if the periodontitis influenced serum and salivary Galectin-3 levels

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Healthy controls (n=38), patients with CHD (n=39), periodontitis (n=40), and a combination of periodontitis + CHD (n=38) were enrolled in the present study. The analyzed sample undergo a demographical, clinical and periodontal evaluation and serological analyses including Endothelin-1 (ET-1) and for serum and salivary Galectin-3 levels.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Periodontal Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control

Observation of salivary Galectin-3 levels and correlation of salivary Galectin -3 evels with periodontal disease

Observation of serum and salivary Galectin-3 levels

Intervention Type OTHER

Observation of serum and salivary Galectin-3 levels and correlation with periodontal indices

Periodontitis

Observation of salivary Galectin-3 levels and correlation of salivary Galectin -3 evels with periodontal disease

Observation of serum and salivary Galectin-3 levels

Intervention Type OTHER

Observation of serum and salivary Galectin-3 levels and correlation with periodontal indices

Coronary heart disease

Observation of salivary Galectin-3 levels and correlation of salivary Galectin -3 evels with periodontal disease

Observation of serum and salivary Galectin-3 levels

Intervention Type OTHER

Observation of serum and salivary Galectin-3 levels and correlation with periodontal indices

Coronary heart disease + periodontitis

Observation of salivary Galectin-3 levels and correlation of salivary Galectin -3 evels with periodontal disease

Observation of serum and salivary Galectin-3 levels

Intervention Type OTHER

Observation of serum and salivary Galectin-3 levels and correlation with periodontal indices

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Observation of serum and salivary Galectin-3 levels

Observation of serum and salivary Galectin-3 levels and correlation with periodontal indices

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Presence of at least 16 teeth
* CP with a minimum of 40% of sites with a clinical attachment level (CAL)

≥2mm and probing depth (PD) ≥4mm;
* Presence of at least ≥2 mm of crestal alveolar bone loss verified on digital periapical radiographs
* Presence of ≥40% sites with bleeding on probing (BOP)

Exclusion Criteria

* Intake of contraceptives
* Intake of immunosuppressive or anti-inflammatory drugs throughout the last three months prior to the study
* Status of pregnancy or lactation
* Previous history of excessive drinking
* Allergy to local anaesthetic
* Intake of drugs that may potentially determine gingival hyperplasia such as Hydantoin, Nifedipine, Cyclosporin A or similar drugs.
Minimum Eligible Age

30 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Messina

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Gaetano Isola, DDS, PhD

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Messina

Messina, , Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

18-16-2018

Identifier Type: -

Identifier Source: org_study_id